Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Page 2 of 12
Jul 28, 2026Alpha-1 antitrypsin deficiency (AATD) was once seen by drug developers as a therapeutic dead end. New genetic tools and emerging industry trends have transformed it into one of biopharma’s hottest battlegrounds, with rapid-fire innovation, complex legal maneuvering, and high-stakes international competition.
Michael Torres
Jul 28, 2026The pursuit of safer treatment options for Alzheimer’s disease—particularly those targeting amyloid—has reached another milestone. Preliminary results from ProMIS Neurosciences highlight the delicate balance between efficacy and safety and may provide new optimism for both clinicians and patients seeking effective interventions.
Michael Torres
Jul 27, 2026In a major regulatory development, Otsuka wins FDA approval for Simtriyo, the world’s first triple reuptake inhibitor for ADHD. The launch opens a new chapter in ADHD drug innovation as the company prepares for commercialization pending DEA scheduling.
Emily Carter
Jul 25, 2026Scribe Therapeutics has set the stage for renewed interest in gene editing companies by completing an initial public offering valued at $129 million. This long-form analysis dives deep into the context, market conditions, scientific promise, and future outlook for not just Scribe but the gene editing sector at large—spotlighting the pursuit of epigenetic silencing therapies and the evolution of CRISPR-derived medicines beyond rare diseases.
Emily Carter
Jul 23, 2026GSK's recently acquired molecule Jideytro (from Nuvalent) has received FDA approval for advanced non-small cell lung cancer driven by ROS1 genetic alterations. This development marks an important outcome of a $10.6 billion merger and positions GSK for a new presence in the competitive lung cancer drug market.
Dr. Priya Nandakumar
Jul 22, 2026As Summit Therapeutics and Akeso unveil new data for their antibody ivonescimab, questions persist about its translation from prior results to Western populations. The ongoing dialogue underscores the complexities facing global drug development and regulatory acceptance, especially as biopharmaceutical partnerships increasingly seek to bridge geographical and genetic divides.
Jonathan Blake
Jul 21, 2026Tempus AI is making headlines with its $1.5 billion agreement to acquire Personalis, fusing two longstanding partners in the high-stakes arena of minimal residual disease (MRD) diagnostics. This move highlights the intensifying demand for non-invasive cancer detection tools and underscores broader shifts in how cancer patients will be diagnosed and monitored.
Dr. Priya Nandakumar
Jul 20, 2026Harnessing advances in cell therapy, Kyverna Therapeutics is approaching an historic FDA submission for a CAR T therapy in autoimmune disease. The company's 'pipeline-in-a-product' strategy highlights both innovation and the ongoing evolution of cell therapies in treating complex immunologic disorders.
Emily Carter
Jul 17, 2026Merck’s newly approved oral PCSK9 inhibitor marks a landmark in the treatment of high cholesterol, promising greater accessibility for patients. The development sees Merck outpace rival firms in delivering a pill-based alternative, which could reshape cholesterol management worldwide.
Sophia Reynolds
Jul 16, 2026Eli Lilly’s $2.8 billion upfront acquisition of AtaiBeckley highlights mainstream industry interest in psychedelic-based therapies for mental illness. This move significantly broadens Lilly's neuroscience portfolio and signals potential shifts in how major pharmaceutical companies approach mental health treatment innovation.
Daniel Cho
Jul 16, 2026Celcuity’s landmark FDA approval of Revtorpyk for advanced breast cancer marks the introduction of a new drug class in oncology. The medicine is approved for cases not characterized by a specific mutation and is aiming to fill a critical gap for many patients facing limited treatment options.
Sophia Reynolds
Jul 15, 2026A new landmark study attempts to decipher the mechanistic link between Epstein-Barr viral infection and the aberrant immune activity characterizing multiple sclerosis. This breakthrough advances our understanding of autoimmune triggers and could shape future research and therapeutic strategies.
Sophia ReynoldsMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.